In summary, our results allowed us to propose and provide evidence to support the SIGIRR/C/EBPβ/TNF-α signaling axis hypothesis in memory CD4 T cells in RA, raising the possibility that receptor reversion can target key abnormalities in T cells and thus representing a potentially novel strategy for immunomodulatory therapy in T cell -mediated autoimmune diseases. This evidence concerns the gene SIGIRR and autoimmune disease.